19,609 Shares in Inhibrx, Inc. (NASDAQ:INBX) Purchased by Deutsche Bank AG

Deutsche Bank AG bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,609 shares of the company's stock, valued at approximately $302,000. Deutsche Bank AG owned approximately 0.14% of Inhibrx at the end of the most recent quarter.

A number of other large investors have also modified their holdings of INBX. PNC Financial Services Group Inc. bought a new position in Inhibrx during the fourth quarter worth about $28,000. Natixis acquired a new position in shares of Inhibrx in the 4th quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. bought a new stake in Inhibrx in the fourth quarter valued at $47,000. New York State Common Retirement Fund acquired a new position in Inhibrx during the fourth quarter worth $53,000. Finally, Corebridge Financial Inc. bought a new position in shares of Inhibrx during the fourth quarter valued at $89,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Inhibrx Price Performance

Shares of NASDAQ:INBX traded down $0.53 during trading on Wednesday, reaching $13.00. The stock had a trading volume of 30,427 shares, compared to its average volume of 114,279. The stock has a market capitalization of $188.19 million and a PE ratio of 0.11. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $18.95. The business's 50-day moving average price is $12.33 and its 200 day moving average price is $13.43.

Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($0.25). Analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current year.

Wall Street Analyst Weigh In

Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a report on Thursday, May 15th.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.